• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DOCETAXEL Drug Record

  • Summary
  • Interactions
  • Claims
  • DOCETAXEL chembl:CHEMBL92 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    RP-56976
    TAXOTERE
    DOCETAXEL, ANHYDROUS
    N-DEBENZOYL-N-(TERT-BUTOXYCARBONYL)-10-DEACETYLTAXOL
    TXL
    DOCETAXEL
    DOCECAD®
    N-DEBENZOYL-N-(TERT-BUTOXYCARBONYL)-10-DEACETYLPACLITAXEL
    EMDOC
    DOCETAXEL ANHYDROUS
    TAXOTERE®
    pubchem.compound:148124
    drugbank:01248
    chemidplus:114977-28-5
    chembl:CHEMBL92
    rxcui:1299922

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    Year of Approval 1996
    Drug Class antineoplastic agents
    Pharmaceutical Developer BIND Biosciences
    Source Reported Drug Name(s) BIND-014/PSMA-targeted docetaxel nanoparticle
    Drug Class Folate Inhibitor
    (8 More Sources)

    Publications:

    He et al., 2013, Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma., Cancer Discov
    Chew SC et al., 2014, Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients., Eur J Clin Pharmacol
    Ikezoe et al., 2004, HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo., Cancer Res.
    Coté D et al., 2018, Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)., PLoS One
    Voon PJ et al., 2013, Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients., Br J Clin Pharmacol
    Rosell et al., 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol.
    Zhou et al., 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study., Lancet Oncol.
    Deeken JF et al., 2010, A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform., Pharmacogenomics J
    Sun et al., 2009, Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients., Lung Cancer
    Edvardsen H et al., 2010, SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance., Pharmacogenomics J
    Yang et al., 2011, p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer., Int. J. Oncol.
    Chen et al., 2012, A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response., Nature
    Lee et al., 2016, Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow., J. Cell. Biochem.
    Oshiro C et al., 2009, Taxane pathway., Pharmacogenet Genomics
    Hohla et al., 2006, Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel., Proc. Natl. Acad. Sci. U.S.A.
    Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res
    Dong et al., 2014, Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression., PLoS ONE
    Younis IR et al., 2014, Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer., Cancer Chemother Pharmacol
    Wacheck et al., 2006, Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells., Cancer Biol. Ther.
    McWhinney-Glass S et al., 2013, Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity., Clin Cancer Res
    Petrylak, 2005, Chemotherapy for androgen-independent prostate cancer., World J Urol
    Marshall et al., 2004, A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors., Ann. Oncol.
    Inoue et al., 2005, Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer., Oncol. Rep.
    Miyoshi et al., 2005, [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]., Nippon Rinsho
    Gligorov et al., 2004, Preclinical pharmacology of the taxanes: implications of the differences., Oncologist
    Magi-Galluzzi et al., 2007, Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study., Cancer
    Baselga et al., 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer., N. Engl. J. Med.
    Swain et al., 2015, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer., N. Engl. J. Med.
    Mackey et al., 2015, Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer., J. Clin. Oncol.
    Blumenthal et al., 2013, First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer., Clin. Cancer Res.
    Martin et al., 2016, Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study., Ann. Oncol.
    Takahashi H et al., 2019, Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma., J Clin Oncol
    Le Morvan V et al., 2015, Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial., Pharmacogenomics J
    Smith et al., 2005, Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel., Cancer Biol. Ther.
    Reimer T et al., 2016, SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study., BMC Cancer
    Marth et al., 1997, Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells., Cancer Res.
    Massacesi et al., Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer., Int. J. Biol. Markers
    Tran et al., 2006, Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms., Clin. Pharmacol. Ther.
    Vidal et al., 2015, A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer., Cancer Cell
    Matesanz et al., 2008, Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel., Chem. Biol.
    Snyder et al., 2001, The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density., Proc. Natl. Acad. Sci. U.S.A.
    Belani et al., 2004, Development of docetaxel in advanced non-small-cell lung cancer., Lung Cancer
    Bosó V et al., 2014, SNPs and taxane toxicity in breast cancer patients., Pharmacogenomics
    Kong SY et al., 2009, Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer., Pharmacogenomics
    Kiyotani K et al., 2008, Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia., Cancer Sci
    De Mattia E et al., 2016, Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine., Pharmacogenomics
    Springate et al., 2005, Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models., Cancer Chemother. Pharmacol.
    Weitzman et al., 2000, Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer., J. Urol.
    Okamura et al., 2000, NADPH/quinone oxidoreductase is a priority target of glioblastoma chemotherapy., Int. J. Oncol.
    Takemura et al., 2005, Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy., J. Oral Pathol. Med.
    Hein A et al., 2015, Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study., Int J Cancer
    Derosa L et al., 2014, Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients., Cancer
    Koutras AK et al., 2014, Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel., Pharmacogenomics J
    Dong N et al., 2012, Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine., J Cancer Res Clin Oncol
    Qian J et al., 2012, Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment., Chest
    Jänne et al., 2015, Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer., Br. J. Cancer
    Gandara et al., 2017, A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer., J Thorac Oncol
    Jänne et al., 2013, Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study., Lancet Oncol.
    Jänne et al., 2017, Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial., JAMA
    Cui et al., 2015, Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer., Clin. Cancer Res.
    Engleson et al., 2006, Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy., BMC Cancer
    Lewis LD et al., 2013, The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)., Pharmacogenet Genomics
    Grünewald S et al., 2019, Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models., Int J Cancer
  • DOCETAXEL   PRDX4

    Interaction Score: 1.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20157331


    Sources:
    PharmGKB

  • DOCETAXEL   ORM2

    Interaction Score: 1.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24619498


    Sources:
    PharmGKB

  • DOCETAXEL   SNORD68

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • DOCETAXEL   XRCC4

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20157331


    Sources:
    PharmGKB

  • DOCETAXEL   SULT1C4

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • DOCETAXEL   CHST3

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • DOCETAXEL   RPL13

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • DOCETAXEL   VAC14

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOCETAXEL   GAS6

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27153245


    Sources:
    CIViC

  • DOCETAXEL   SPG7

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • DOCETAXEL   CYP4B1

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • DOCETAXEL   ABCC6

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • DOCETAXEL   RNF8

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30071039


    Sources:
    PharmGKB

  • DOCETAXEL   SOX10

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23963862


    Sources:
    PharmGKB

  • DOCETAXEL   TLE3

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • DOCETAXEL   SLC10A2

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • DOCETAXEL   BARD1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30071039


    Sources:
    PharmGKB

  • DOCETAXEL   MDM4

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24958282


    Sources:
    PharmGKB

  • DOCETAXEL   MUC16

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9288793 14756546


    Sources:
    NCI

  • DOCETAXEL   ATP7A

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • DOCETAXEL   ACSS2

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • DOCETAXEL   PGP

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • DOCETAXEL   EPHX1

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20157331


    Sources:
    PharmGKB

  • DOCETAXEL   PPCDC

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOCETAXEL   MAP3K1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • DOCETAXEL   FBXW7

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    23274910


    Sources:
    JAX-CKB

  • DOCETAXEL   NR1I3

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27561454 24193570


    Sources:
    PharmGKB

  • DOCETAXEL   BCL2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name BIND-014
    Novel drug target Established target
    Trial Name Docetaxel

    PMIDs:
    23963862 15685445 15277270 15643508 15714982 15161985 17674353


    Sources:
    TdgClinicalTrial PharmGKB

  • DOCETAXEL   ERCC2

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25495407


    Sources:
    PharmGKB

  • DOCETAXEL   XRCC1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19157633


    Sources:
    CIViC

  • DOCETAXEL   AKR1C3

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23116553


    Sources:
    PharmGKB

  • DOCETAXEL   FOLH1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Prostate

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial CancerCommons

  • DOCETAXEL   BRD4

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16542442


    Sources:
    NCI

  • DOCETAXEL   KLK3

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15864591 10687988


    Sources:
    NCI

  • DOCETAXEL   SLCO1B3

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21151855 18294295


    Sources:
    PharmGKB

  • DOCETAXEL   IGF2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25670080


    Sources:
    CIViC

  • DOCETAXEL   RRM1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24647522


    Sources:
    CIViC

  • DOCETAXEL   HNF4A

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24193570


    Sources:
    PharmGKB

  • DOCETAXEL   NOTCH1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy PF-03084014 + Docetaxel
    Indication/Tumor Type prostate cancer
    Response Type predicted – sensitive

    PMIDs:
    26202948


    Sources:
    JAX-CKB

  • DOCETAXEL   ERCC1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25495407


    Sources:
    PharmGKB

  • DOCETAXEL   TUBB1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name ANX-514, lyophilized docetaxel
    Novel drug target Established target
    Trial Name ATI-1123

    PMIDs:
    15161985 18559268 11309480 15698529


    Sources:
    TdgClinicalTrial TEND

  • DOCETAXEL   NAT2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • DOCETAXEL   VEGFA

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26100253 25111199 24061601


    Sources:
    PharmGKB

  • DOCETAXEL   RAF1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • DOCETAXEL   CASP7

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22441531


    Sources:
    PharmGKB

  • DOCETAXEL   CYP1A1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22426923


    Sources:
    PharmGKB

  • DOCETAXEL   GSTM1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16765145


    Sources:
    NCI

  • DOCETAXEL   STK11

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22425996


    Sources:
    CIViC

  • DOCETAXEL   CYP2A6

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19604090


    Sources:
    PharmGKB

  • DOCETAXEL   SLCO1B1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16210916 27234217


    Sources:
    NCI PharmGKB

  • DOCETAXEL   ABCC2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23188068 21151855 18294295


    Sources:
    PharmGKB

  • DOCETAXEL   CYP1B1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21151855


    Sources:
    PharmGKB

  • DOCETAXEL   TUB

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • DOCETAXEL   ERBB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Docetaxel + T-DM1 + Pertuzumab
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    22149875 25693012 30071039 25185099 23801166 27052654 30452336


    Sources:
    JAX-CKB CIViC PharmGKB

  • DOCETAXEL   ERBB3

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30071039


    Sources:
    PharmGKB

  • DOCETAXEL   HRAS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16983095


    Sources:
    NCI

  • DOCETAXEL   KRAS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Selumetinib + Docetaxel
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type no benefit

    PMIDs:
    26125448 27876675 23200175 28492898


    Sources:
    JAX-CKB CIViC

  • DOCETAXEL   MCL1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16969094


    Sources:
    NCI

  • DOCETAXEL   BAX

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15641988


    Sources:
    NCI

  • DOCETAXEL   GSTP1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10639573


    Sources:
    NCI

  • DOCETAXEL   ABCC1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21151855


    Sources:
    PharmGKB

  • DOCETAXEL   PGR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • DOCETAXEL   ABCG2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21151855


    Sources:
    PharmGKB

  • DOCETAXEL   CYP19A1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOCETAXEL   BIRC5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • DOCETAXEL   RXRA

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24193570


    Sources:
    PharmGKB

  • DOCETAXEL   NR1I2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    24193570 15492266


    Sources:
    PharmGKB

  • DOCETAXEL   TUBB3

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • DOCETAXEL   FGFR1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30807645


    Sources:
    CIViC

  • DOCETAXEL   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21151855


    Sources:
    PharmGKB

  • DOCETAXEL   OPRM1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23963862


    Sources:
    PharmGKB

  • DOCETAXEL   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22285168 21783417


    Sources:
    PharmGKB

  • DOCETAXEL   ESR2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOCETAXEL   PPARD

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20038957


    Sources:
    PharmGKB

  • DOCETAXEL   PIK3CA

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20157331


    Sources:
    PharmGKB

  • DOCETAXEL   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase I
    Response Type sensitive

    PMIDs:
    21399868 22425996


    Sources:
    JAX-CKB CIViC

  • DOCETAXEL   ESR1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • DOCETAXEL   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21151855


    Sources:
    PharmGKB

  • CancerCommons: DOCETAXEL

    • Version: 25-July-2013

    Alternate Names:
    Docetaxel Drug Trade Name
    Docetaxel Drug Development Name

    Drug Info:
    Drug Class Folate Inhibitor
    Source Reported Drug Name(s) BIND-014/PSMA-targeted docetaxel nanoparticle
    Pharmaceutical Developer BIND Biosciences

    Publications:

  • TEND: DOCETAXEL

    • Version: 01-August-2011

    Alternate Names:
    DOCETAXEL Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agents
    Year of Approval 1996

    Publications:

  • TdgClinicalTrial: DOCETAXEL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: DOCETAXEL

    • Version: 14-September-2017

    Alternate Names:
    C1526 NCI drug code

    Drug Info:

    Publications:
    Tran et al., 2006, Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms., Clin. Pharmacol. Ther.
    Takemura et al., 2005, Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy., J. Oral Pathol. Med.
    Engleson et al., 2006, Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy., BMC Cancer

  • JAX-CKB: Docetaxel

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    He et al., 2013, Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma., Cancer Discov
    Blumenthal et al., 2013, First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer., Clin. Cancer Res.
    Martin et al., 2016, Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study., Ann. Oncol.

  • PharmGKB: docetaxel

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Chew SC et al., 2014, Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients., Eur J Clin Pharmacol
    Voon PJ et al., 2013, Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients., Br J Clin Pharmacol
    Edvardsen H et al., 2010, SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance., Pharmacogenomics J

  • CIViC: DOCETAXEL

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Jänne et al., 2013, Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study., Lancet Oncol.
    Gandara et al., 2017, A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer., J Thorac Oncol
    Jänne et al., 2015, Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer., Br. J. Cancer

  • TTD: Docetaxel

    • Version: 2020.06.01

    Alternate Names:
    D0O5WP TTD Drug ID

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: DOCETAXEL

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL92

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: DOCETAXEL

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Docetaxel

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21